Probiodrug

Probiodrug AG is a Germany-based biopharmaceutical company active in the biotechnology & medical research industry. The Company is focused on the research and development of therapeutic products for the treatment of Alzheimer’s disease. It develops drugs to target toxic pyroglutamate-Abeta (pGlu-Abeta) via two modes of action, by inhibiting the production of pGlu-Abeta; and clearing existing pGlu-Abeta from the brain. The Company develops specific inhibitors for the enzyme Glutaminyl Cyclase (QC) helping in the creation of pGlu-Abeta and engineers a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Probiodrug AG’s pipeline includes the molecule inhibitors PQ912, PQ1565 and a monoclonal antibody PBD-C06.
Type
Public
HQ
Halle (Saale), DE
Founded
1997
Size (employees)
16 (est)
Probiodrug was founded in 1997 and is headquartered in Halle (Saale), DE

Probiodrug Office Locations

Probiodrug has office in Halle (Saale)
Halle (Saale), DE

Probiodrug Metrics

Probiodrug Summary

Market capitalization

€113.1 m

Closing share price

€15.2
Probiodrug's current market capitalization is €113.1 m.

Probiodrug Market Value History

Probiodrug Online Presence

Probiodrug Company Life

You may also be interested in